Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
| CAPS Rating |
|
|---|---|
| Open | $103.00 |
| Previous Close | $103.60 |
| Daily Range | $101.29 - $103.84 |
| 52-Week Range | $34.05 - $105.42 |
| Market Cap | $9.35B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 801,188 |
| Average Daily Volume | 0 |
REGN
VS S&P 500 (SPY)
How do you think REGN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
REGN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
REGN News and Commentary
- EUROPEAN MIDDAY BRIEFING FROM DOW JONES NEWSWIRES – SmartMoney
- EUROPEAN MIDDAY BRIEFING FROM DOW JONES NEWSWIRES – SmartMoney
- EUROPEAN MIDDAY BRIEFING FROM DOW JONES NEWSWIRES – SmartMoney
- 3 Lessons From the J.P. Morgan Health-Care Confab – The Motley Fool
- REGN Projects Strong Q4 Eylea Sales - Analyst Blog – NASDAQ
- The Sector That's Delivering 2012's Biggest Winners – The Motley Fool
- A Year's Worth of Sales in 1 Month – The Motley Fool
- Linear Growth Isn't Enough – The Motley Fool
- Regeneron Pharmaceuticals Shares Jumped: What You Need to Know – The Motley Fool
- Regeneron Blows Away Sales Forecast for New Eye Drug – Minyanville
- Regeneron to Lift Veil on Eye Drug Success – Minyanville
- Regeneron Settles Dispute - Analyst Blog – NASDAQ
- EUROPEAN MIDDAY BRIEFING FROM DOW JONES NEWSWIRES – SmartMoney
- You Probably Just Bought These Stocks – The Motley Fool
- Dendreon 2011: Supply Constrained to Missed Guidance – The Motley Fool
- These Companies Will Make Big Moves This Friday – The Motley Fool
- FDA Irony: Less Data, Longer Review – The Motley Fool
- A Soaring Biotech With Room to Run – The Motley Fool
- Regeneron's Eylea Data Unimpressive - Analyst Blog – NASDAQ
- 4 Investments That Everybody Loves – The Motley Fool
RSS Headlines
Fool UK
